As of 2025-05-31, the Intrinsic Value of Bukwang Pharm Co Ltd (003000.KS) is 2,298.96 KRW. This 003000.KS valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 4,005.00 KRW, the upside of Bukwang Pharm Co Ltd is -42.60%.
The range of the Intrinsic Value is 1,331.13 - 6,737.48 KRW
Based on its market price of 4,005.00 KRW and our intrinsic valuation, Bukwang Pharm Co Ltd (003000.KS) is overvalued by 42.60%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 1,331.13 - 6,737.48 | 2,298.96 | -42.6% |
| DCF (Growth 10y) | 1,494.36 - 6,986.50 | 2,492.11 | -37.8% |
| DCF (EBITDA 5y) | 2,412.53 - 4,548.65 | 3,688.41 | -7.9% |
| DCF (EBITDA 10y) | 2,761.70 - 6,209.57 | 4,513.05 | 12.7% |
| Fair Value | -58.36 - -58.36 | -58.36 | -101.46% |
| P/E | (141.47) - 435.56 | 72.06 | -98.2% |
| EV/EBITDA | 793.83 - 2,595.65 | 1,704.20 | -57.4% |
| EPV | (573.54) - (1,128.98) | (851.26) | -121.3% |
| DDM - Stable | (130.03) - (1,004.41) | (567.22) | -114.2% |
| DDM - Multi | 1,790.59 - 11,126.98 | 3,122.24 | -22.0% |
| Market Cap (mil) | 274,142.25 |
| Beta | 1.12 |
| Outstanding shares (mil) | 68.45 |
| Enterprise Value (mil) | 266,487.66 |
| Market risk premium | 5.82% |
| Cost of Equity | 7.66% |
| Cost of Debt | 24.70% |
| WACC | 10.10% |